诺和诺德CagriSema头对头替尔泊肽减重III期研究未达主要终点

医药魔方
Feb 23

2月23日,诺和诺德宣布CagriSema对比替尔泊肽的减重III期REDEFINE 4研究未达到主要终点。CagriSema为诺和诺德开发的一款复方药物,包含长效胰淀素(amylin)类似物Cagrilintide与GLP-1受体激动剂司美格鲁肽。2025年12月,该复方已在美国申报上市,申报的适应症为:在减少热量饮食和增加体力活动的基础上,长期降低体重并维持体重减轻,适用于肥胖(BMI≥...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10